表紙/オレンジDIC164 背4.5mm
|
|
- ともみ やぶき
- 5 years ago
- Views:
Transcription
1 An overview of regular dialysis treatment in Japan as of Dec. 31, 2004 Japanese Society for Dialysis Therapy
2 An overview of regular dialysis treatment in Japan as of Dec. 31, 2004 Japanese Society for Dialysis Therapy
3
4 DOS/V CD-ROM , , , FAX Key man 513 3,8823,
5 ,16610, Web,CD- ROM Key man
6 v
7 HCO D 32 2 D 33 3 D 34 4 D 35 5D 36 6D 37 7PTH D 38 8PTH D 39 1PTX 40 2PEIT 41 vi
8 LDL HDL PTH vii
9
10 2 3, % 97,3664,6565.0% 96,5404, ,79816,7945.4% ,9323,882(98.73%) 2004
11 3 248,16610, , / / / / 1, / 3, / 6, / 9, / 13, / 18, / 22, / 27, / 32, / 36, / 42, / 47, / 53, / 59, / 66, / 73, / 80, / 88, / 83, / 103, / 116, / 3, / 134, / 143, / 154, / 167, / 175, / 185, / 197, / 206, / 219, / 229, / 237, / 248,166
12 300, , , , ,000 50, ,017 11,348 4,538 59,811,606 5,000 66,310 13,416 5,770 73,537 14,175 6,296 80,553 14,699 6,581 88,534 16,470 7,765 83,221 14,174 6, ,296 18,411 8, ,303 20,877 9,722 3,926 22,475 11, ,298 23,874, ,709 24,296 13, ,413 26,398 14, ,192 28,409 15, ,988 28,870 16, ,322 29,641 16, ,213 31,483 18, ,134 32,018 18, ,183 33,243 19, ,538 33,710 20, ,710 33,966 21, ,166 35,084 22, , ,118(3.3%) 22,7151,043(4.8%) 1 4
13 , , , , , , , , , , , , ,
14 ,3664,6565.0% 1966/ 1968/ / / / 3, / 1, / 4, / 5, / 7, / 9, / 10, /, / 16, / 18, / 21, / 22, / 24, / 26, / 1986/ 30,846 28, / 36, / 33, / 40, / 34, / 45, / 49, / 53, / 58, / 59, / 63, / 66, / 69, / 75, / 79, / 83, / 89, / 92, / 97,366
15 %17.2% CAPD3.5%CAPD4% CAPD8, ,255 2,304 1,997 2,941 1,566 1,486 3,085 4,508 3,728 3,444 9,613 8,0 18,606 11,193 3,164 1,607 1,821 1,143 1,566 3,259 2,779 6,378 9,559 2,557 1, ,096 2,041 4,830 2,770 1, ,289 3, ,597 3,644 14,541 8,219 2,243 2, ,925 4,721 2,304 1,683 1,863 2,347 1,500 8,569 1,357 2,584 4,180 2,624 2,517 3,716 2, , ,201 3,165 1, , , , ,085 2,641 2,529 3,840 1,788 1,935 3,827 5,488 4,516 4,289,079 10,302 24,136 14,490 4,333 2,038 2,221 1,422 1,805 4,000 3,562 8,015 13,315 3,375 2,113 5,004 18,477 10,223 2,560 2,421 1,155 1,224 3,828 5,876 2,840 2,150 2,276 2,918 1,845 11,178 1,645 3,169 5,209 3,103 3,097 4,400 3, ,166
16 8,085 2,641 2,529 3,840 1,788 1,935 3,827 5,488 4,516 4,289,079 10,302 24,136 14,490 4,333 2,038 2,221 1,422 1,805 4,000 3,562 8,015 13,315 3,375 2,113 5,004 18,477 10,223 2,560 2,421 1,155 1,224 3,828 5,876 2,840 2,150 2,276 2,918 1,845 11,178 1,645 3,169 5,209 3,103 3,097 4,400 3, , ,000 10,000 15,000 20,000 25,000
17 % % % % %252.9% ,
18 ,830 (0.0) (0.0) (0.0) (0.4) (0.7) (1.4) (2.0) (2.6) (4.5) (8.5) (0.0) (0.0) (0.3) (0.7) (1.1) (1.7) (2.2) (3.5) (6.7) ,397 2,659 (0.0) (0.0) (0.0) (0.4) (0.7) (1.3) (1.9) (2.5) (4.1) (7.8) 2,433 2,773 3,2 3,388 2,909 1, , , (11.3) (.9) (14.9) (15.7) (13.5) (7.6) (3.1) (0.6) (100.0) 1,103 1,403 1,680 1,871 1,889 1, ,3 50, (9.0) (11.4) (13.6) (15.2) (15.3) (11.8) (5.5) (1.5) (100.0) 3,536 4,176 4,892 5,259 4,798 3,095 1, , , (10.4) (.3) (14.4) (15.5) (14.2) (9.1) (4.0) (0.9) (100.0) ,0841,118(3.3%) 33,87721,565,
19 %28.1% 9.3%8.8% , , , (28.1) (0.9) (1.1) (0.2) (0.4) (2.7) (8.8) (0.7) (41.3) (0.8) (0.4) (0.3) ,3 33, ,935 (0.2) (0.4) (0.3) (0.4) (0.7) (2.8) (9.3) (100.0)
20 % 28.1% % 8.8 SLE
21 ,132 3,510 5,052 7,919 14,253 20,331 21,911 21,525 19,850 14,481 7,321 2, (0.0) (0.0) (0.0) (0.2) (0.7) (1.5) (2.4) (3.5) (5.5) (9.9) (14.2) (15.3) (15.0) (13.8) (10.1) (5.1) (1.9) (0.5) ,133 1,903 2,882 4,595 8,644,149 13,054 13,217,339 10,775 7,214 3, (0.0) (0.0) (0.0) (0.2) (0.5) (1.2) (2.0) (3.1) (4.9) (9.3) (13.1) (14.0) (14.2) (13.3) (11.6) (7.8) (3.6) (1.0) ,469 3,265 5,413 7,934,514 22,897 32,480 34,965 34,742 32,189 25,256 14,535 6,094 1, (0.0) (0.0) (0.0) (0.2) (0.6) (1.4) (2.3) (3.4) (5.3) (9.7) (13.7) (14.8) (14.7) (13.6) (10.7) (6.1) (2.6) (0.7) 143,389 (100.0) , ,031 (100.0) 45 93, ,420 (100.0) ,
22 106,458 (45.1) ,977 1,437 1,760 1,076 7,933 13,485 1,785 (1.3) (0.6) (0.7) (0.5) (3.4) (5.7) (0.8) ,394 (30.2) , , (0.9) (0.2) (0.5) ,596 4,050 15,219 (0.2) (0.2) (0.2) (0.3) (0.2) (0.7) (1.7) (6.4) ,034 (100.0) , % 30.2%1/
23 ß 15
24
25 ICD-10 (24.3%)(21.9%)(10.6%) (25.3%)(22.6%)(6.8%) 385 (21.9) 108 (6.2) 427 (24.3) 32 (1.8) 186 (10.6) 39 (2.2) 71 (4.0) 56 (3.2) 48 (2.7) 281 (25.3) 72 (6.5) 251 (22.6) 33 (3.0) 75 (6.8) 40 (3.6) 39 (3.5) 52 (4.7) 13 (1.2) 666 (23.2) 180 (6.3) 678 (23.7) 65 (2.3) 261 (9.1) 79 (2.8) 110 (3.8) 108 (3.8) 61 (2.1) 668 (23.3) 182 (6.3) 678 (23.6) 65 (2.3) 261 (9.1) 79 (2.8) 110 (3.8) 108 (3.8) 61 (2.1) 2 (50.0) 2 (50.0) 1 24 (1.4) 8 (0.5) 15 (0.9) 8 (0.5) 205 (11.7) 143 (8.1) 1,756 (100.0) 17 1, (0.7) 7 (0.6) 6 (0.5) 3 (0.3) 152 (13.7) 77 (6.9) 1,110 (100.0) 1, (1.1) 15 (0.5) 21 (0.7) 11 (0.4) 357 (.5) 220 (7.7) 2,866 (100.0) 29 2,895 4 (100.0) (1.1) 15 (0.5) 21 (0.7) 11 (0.4) 357 (.4) 220 (7.7) 2,870 (100.0) 30 2,900
26 %23.3%9.1%6.3% 3.8% % 18
27 ,991 (23.4) 1,318 (10.3) 2,423 (18.9) 253 (2.0) 1,311 (10.3) 266 (2.1) 741 (5.8) 689 (5.4) 245 (1.9) 2,185 (27.7) 871 (11.1) 1,459 (18.5) 198 (2.5) 553 (7.0) 219 (2.8) 379 (4.8) 382 (4.9) 83 (1.1) 5,176 (25.0) 2,189 (10.6) 3,882 (18.8) 451 (2.2) 1,864 (9.0) 485 (2.3) 1,0 (5.4) 1,071 (5.2) 328 (1.6) 2 (50.0) 2 (50.0) 5,178 (25.1) 2,191 (10.6) 3,882 (18.8) 451 (2.2) 1,864 (9.0) 485 (2.3) 1,0 (5.4) 1,071 (5.2) 328 (1.6) (1.1) 100 (0.8) 54 (0.4) 95 (0.7) 1,252 (9.8) 898 (7.0),790 (100.0) 158, (0.7) 90 (1.1) 30 (0.4) 25 (0.3) 887 (11.3) 450 (5.7) 7,876 (100.0) 106 7, (1.0) 190 (0.9) 84 (0.4) 0 (0.6) 2,139 (10.4) 1,348 (6.5) 20,666 (100.0) ,930 4 (100.0) (1.0) 190 (0.9) 84 (0.4) 0 (0.6) 2,139 (10.3) 1,348 (6.5) 20,670 (100.0) ,936
28 % % 10.6% 6.2%5.4% PTCACABG 20
29 %8.5%9.29.3% % 21
30 %86.0% 62.3%60.2%1039.3% % % ,050,036,971 14,238 15,424 16,951 16,908 19,339 21,364 23,231 24,540 25,280 27,047 29,510 30,362 31,994 33,578 36,503 37,973 38,293 38,
31
32 %75.1% 119,532 (75.1) 8,442 (76.7) 29 (61.7) 251 (73.2) 69 (75.0) 2,878 (68.5) 118 (79.7) 35,503 (26.2) 3,460 (37.4) 10 (20.4) 118 (39.5) 32 (35.6) 1,060 (28.5) 38 (40.4) 1,432 (1.1) 160 (1.9) 6 (13.3) 1 (0.4) 79 (2.2) 3,213 (2.5) 587 (6.2) 1 (2.6) 35 (11.2) 2 (2.2) 90 (2.5) 3 (3.1) D HCO3PTXPEIT
33 26 1.5g3.0g3.0g6.0g 9g6.0g 731 (1.8) 4,993 (.4) 15,218 (37.9) 15,028 (37.4) 3,083 (7.7) 1,8 (2.8) ,
34 PTH mg/dlmeq/l PTH 27
35 HCO3 HCO3 28
36 29 1.5g3.0g 3.0g4.5g 8,264 (6.3) 47,819 (36.5) 50,223 (38.3) 13,944 (10.6) 7,338 (5.6) 1,947 (1.5) 1,531 (1.2) , (%)
37 PTH 24PTH PTHD 30
38 1,382 7,583 7,220 2,316 1, , (21.6) (20.8) (19.1) (21.9) (24.6) (23.1) (21.2) (.0) (32.4) (42.9) 32.4% 6.0g9.0g 24.6% 31
39 32 D D D CAPDD CAPD 48,388 (29.2) 3,184 (27.1) (21.1) 87 (24.0) 22 (23.2) 1149 (25.1) 38 (25.5) 15,687 (9.5) 1,094 (9.3) 3 (5.3) 35 (9.7) 16 (16.8) 557 (.2) 33 (22.1) 3,904 (2.4) 425 (3.6) 13 (3.6) 13 (13.7) 296 (6.5) 5 (3.4) 1,032 (0.6) 78 (0.7) 2 (3.5) 35 (0.8) 95,917 (57.8) 6,911 (58.9) 40 (70.2) 226 (62.4) 44 (46.3) 2,463 (53.8) 72 (48.3) 947 (0.6) 39 (0.3) 1 (0.3) 75 (1.6) 1 (0.7)
40 6,822 (4.1) 671 (5.8) 1 (1.7) 27 (7.4) 19 (0.4) 18,359 (11.1) 2,030 (17.4) 7 (.1) 86 (23.7) 9 ( 9.5) 3 ( 2.7) 6 ( 4.1) (0.5) 1 (0.3) 138,605 (84.1) 8,860 (76.1) 50 (86.2) 248 (68.3) 86 (90.5) 4,309 (94.9) 139 (95.2) 748 (0.5) 36 (0.3) 1 (0.3) 89 (2.0) 1 (0.7) D 15%D CAPD3%CAPDD 33
41 13,835 (31.7) 4,377 (10.0) 831 (1.9) 353 (0.8) 23,968 (54.9) 311 (0.7) 15,151 (31.5) 4,564 (9.5) 1,159 (2.4) 353 (0.7) 26,660 (55.4) 235 (0.5),492 (27.5) 4,041 (8.9) 1,231 (2.7) 264 (0.6) 27,136 (59.7) 263 (0.6) 5,430 (25.0) 1,927 (8.9) 705 (3.2) 90 (0.4) 13,436 (61.9) 106 (0.5) 2,705 (23.9) 1,136 (10.0) 348 (3.1) 37 (0.3) 7,017 (62.0) 82 (0.7) 1,746 (24.5) 768 (10.8) 224 (3.1) 27 (0.4) 4,324 (60.7) 35 (0.5) 1,521 (27.8) 6 (11.2) 158 (2.9) 23 (0.4) 3,132 (57.2) 31 (0.6) D D20 34
42 925 (2.1) 2,4 (4.9) 41 39,679 (92.1) 298 (0.7) 1,521 (3.2) 3,417 (7.2) 46 42,449 (89.1) 226 (0.5) 2,025 (4.5) 5,499 (.2) 89 (0.2) 37,402 (82.7) 204 (0.5) 1,327 (6.1) 4,276 (19.7) 42 (0.2) 15,973 (73.7) 69 (0.3) 860 (7.6) 2,625 (23.1) 24 (0.2) 7,813 (68.7) 43 (0.4) 494 (6.9) 1,613 (22.6) 26 (0.4) 4,992 (69.9) 18 (0.3) 388 (7.1) 1,066 (19.5) 18 (0.3) 3,989 (72.8) 17 (0.3) D D20 PTX 35
43 36 D 0.75g3.0 g 4,823 (9.2) 1,502 (8.7) 767 (16.6) 29,463 (56.2) 11,357 (65.6) 3,723 (80.7) 16,140 (30.8) 3,973 (23.0) 88 (1.9) 1,786 (3.4) 370 (2.1) 11 (0.2) 259 (0.5) 99 (0.6) 27 (0.6) , ,673 1,063
44 492 (6.5) 1,035 (13.8) 2,844 (37.8) 2,7 (28.3) 1,028 (13.7) 14 3,271 (16.0) 6,342 8,007 2, (31.0) (39.1) (13.2) (0.7) , D 1.5g3.0g3.0g4.5g 15.0g30.0g7.5g15.0g 37
45 4,501 4,832 4,010 3,615 3,314 3,050 2,896 2,390 2,319 2,028 8,698 2, (33.2) (33.6) (32.1) (31.1) (31.0) (31.8) (30.9) (28.7) (28.9) (28.1) (25.8) (18.7) (13.7) (10.8) (10.7) 1,731 1,472 1,215 1,107 1, ,169 1, (.8) (10.2) (9.7) (9.5) (9.5) (9.6) (9.2) (9.6) (9.0) (9.3) (9.4) (7.6) (6.2) (5.9) (5.9) , (1.5) (1.5) (1.5) (1.6) (2.0) (2.3) (2.3) (2.6) (3.0) (2.9) (4.1) (4.2) (3.6) (4.3) (3.2) (0.8) (0.7) (0.7) (0.6) (0.5) (0.7) (0.5) (0.5) (0.5) (0.7) (0.5) (0.4) (0.2) (0.3) 6,976 7,687 6,935 6,578 6,058 5,305 5,319 4,844 4,674 4,231 20,170 9,182 2,548 1,152 1,209 (51.4) (53.5) (55.6) (56.6) (56.6) (55.2) (56.7) (58.1) (58.2) (58.5) (59.8) (68.4) (75.8) (78.2) (79.5) (0.3) (0.5) (0.4) (0.5) (0.4) (0.4) (0.5) (0.5) (0.4) (0.5) (0.5) (0.6 (0.7) (0.7) (0.5) PTHD PTH200pg/mlD PTHDPTH PTHD D 38
46 ,482 1, (0.7) (0.7) (1.0) (1.4) (1.7) (2.3) (2.9) (3.5) (4.6) (5.3) (7.3) (.1) (13.9) (13.6) (14.8) ,968 4,602 1, (1.0) (1.7) (2.5) (3.2) (4.4) (5.5) (7.2) (9.3) (11.1) (.8) (20.6) (33.7) (39.1) (40.3) (36.8) (0.0) (0.2) (0.2) (0.2) (0.3) (0.5) (0.7) (0.3),934 13,656 11,757 10,849 9,866 8,649 8,286 7,113 6,676 5,843 24,173 7,302 1, (97.9) (97.3) (96.1) (95.0) (93.5) (91.6) (89.3) (86.3) (83.8) (81.3) (71.4) (53.4) (46.0) (45.1) (47.9) (0.3) (0.3) (0.4) (0.4) (0.4) (0.6) (0.5) (0.6) (0.3) (0.5) (0.4) (0.3) (0.3) (0.7) (0.5) PTHD DPTHD PTH 600pg/ml 39
47 160,694 9, ,551 (92.1) (5.4) (0.3) (0.0) (0.0) (0.0) (2.0) PTX 6%PTX 40
48 167,952 1, ,243 (96.7) (0.9) (0.2) (0.0) (0.0) (0.0) (0.0) (1.9) PEIT PEIT2,4811,576 PEIT 41
49
50 2003 LDL HDL- PTH end point PTH ,933 end point censored case end point censored case ,214 end point censored case 45
51 ,715 end point2004 Lacunar Infarction 2004 censored case ,474 end point censored case Cox
52 47
53 180mg/dl 240mg/dl mg/dl mg/dl mg/dl 48
54 160mg/dl 160mg/dl 160mg/dl 200mg/dl 220mg/dl 160mg/dl 49
55 80mg/dl LDL LDL 60mg/dl LDL LDL 50
56 100mg/dl LDL LDL100mg/dl LDL60mg/dl LDLp= mg/dl LDL 51
57 52 HDL- HDL- HDL- HDL- HDL-
58 HDL-30mg/dl HDL- 53
59 50mg/dl 54
60 50mg/dl 200mg/dl mg/dl 55
61 meq/l mg/dl 9mg/dl 11mg/dl 8mg/dl 11mg/dl 56
62 57
63 56mg/dl 4mg/dl 8mg/dl 6mg/dl 58
64 4mg/dl 59
65
66 70 61
67 60pg/ml 360pg/ml PTH 60pg/ml 720pg/ml PTH 3060pg/ml0360pg/ml PTH 30pg/ml 360pg/ml PTH 62
68 63
69 3.5mEq/L mEq/L mEq/L3.5mEq/L mEq/L 64
70 mEq/L 2.5mEq/L 65
71 66
72 67
73
74 70
75 71
76 An overview of regular dialysis treatment in Japan as of Dec. 31, 2004
,g,g,g,9g
9 -- ,g,g,g,9g 9 9 9 9 () ( ),9.9,,9 9,.9 9,, () () () 9 9 9,9 9 9 9 (),,9 9, 9 9, 9 9 9 9 9 9 9 9 9, 9,, (),9.,,,9 9,. 9,9 9, 9,,,. 9,9 9,,,,.,,,9,,.9,,,9,,.,,,,,.,9,9,,,. 9,9,,99,,.,9, 9,,,.,,9,9 99,9.,
More information38
979 25 98 594 324 333 348 347 35 23 78 44 758 37 38 24 8 2 7 44 32 8 2 2 24 7 4 3 2 9 8 7 3 6 4 3 7 4 8 2 5 2 6 3 24 8 3 74 46 344 9 6 2 3 2 24 7 4 3 2 2 9 9 7 3 2 4 3 758 223 39 () 96.5g (2),33.6g 24.572g,33.6g
More information[] 1
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
More information199004_渓仁会_年次報告書
() () () () () () () () () () () () () () () (4) (5) (6) 4 (7) 5 (8) 6 (9) 7 () 8 () 7 4 5 () 6 () 6 7 9 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 44 45 () 4 46 () 48 () 48 () 49 () 49 5 () 5 () 5 ()
More informationt Z
t Z 1 11 1 1 1 1 1 1 1 1 1 1 1 1 UU 1 as a s 1 1 1 1 1 1 G q w e r q q w e r a s 1 1 1 1 1 1 1 a s a gg g q w e r 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
More informationi
i KEY WORDS CASE CHECK POINT EXERCISE Column ii 4 6 9 11 1 5 7 8 2 3 10 12 MESSAGE iii 1 1 23 4 2 56 3 2 5 8 11 CASE 12 1 2 3 181920 20 4 2223 232425 5 6 14 16 18 22 25 27 29 CASE 30 1 31 3233 2 31 34
More informationV. 7 1 ICD ICD F00 F99 2 ICD G40 3 1 1. 2. 3. 4. 2 1. 2. 3. 4. 3 1. 2. 3. 4 1. 2. 3. 4. 5 1. 2. 3. 4. 6 1. 2. 3. 4. 5. 6. 7 1. 2. 3. 4. 5. 8 1. 2. 3. 9 1. 2. 3. 4..... 10 1.... 2. 3. 4..... 5. 6. 7.
More information年次報告書-2003年(平成15年)度版-
9876 ,g,g,g,9g 8 6 6 6 6 8 7 8 6 7 8 7 9 7 6 6 6 7 7 8 6 8 7 6 6 8 7 8 7 7 9 7 6 98 76,8 () ( ) 8,68.7 7,76, 9,87.9 8,67, () g g g g g g g g g g g g g g g g g g g g g g g g g g g g () () 9 8 88 6 8 88
More informationワタベウェディング株式会社
1 2 3 4 140,000 100,000 60,000 20,000 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 5 6 71 2 13 14 7 8 9 10 11 12 1 2 2 point 1 point 2 1 1 3 point 3 4 4 5 6 point 4 point 5 point 6 13 14 15 16 point 17
More informationp01.qxd
2 s 1 1 2 6 2 POINT 23 23 32 15 3 4 s 1 3 2 4 6 2 7003800 1600 1200 45 5 3 11 POINT 2 7003800 7 11 7003800 8 12 9 10 POINT 2003 5 s 45700 3800 5 6 s3 1 POINT POINT 45 2700 3800 7 s 5 8 s3 1 POINT POINT
More information株主通信:第18期 中間
19 01 02 03 04 290,826 342,459 1,250,678 276,387 601,695 2,128,760 31,096 114,946 193,064 45,455 18,478 10,590 199,810 22,785 2,494 3,400,763 284,979 319,372 1,197,774 422,502 513,081 2,133,357 25,023
More information1003shinseihin.pdf
1 1 1 2 2 3 4 4 P.14 2 P.5 3 P.620 6 7 8 9 10 11 13 14 18 20 00 P.21 1 1 2 3 4 5 2 6 P7 P14 P13 P11 P14 P13 P11 3 P13 7 8 9 10 Point! Point! 11 12 13 14 Point! Point! 15 16 17 18 19 Point! Point! 20 21
More information株主通信 第16 期 報告書
10 15 01 02 1 2 3 03 04 4 05 06 5 153,476 232,822 6,962 19,799 133,362 276,221 344,360 440,112 412,477 846,445 164,935 422,265 1,433,645 26,694 336,206 935,497 352,675 451,321 1,739,493 30,593 48,894 153,612
More informationヤフー株式会社 株主通信VOL.16
01 260,602264,402 122,795125,595 64,84366,493 107110 120,260123,060 0 500 300 400 200 100 700 600 800 39.8% 23.7% 36.6% 26.6% 21.1% 52.4% 545 700 0 50 200 150 100 250 300 350 312 276 151 171 02 03 04 POINT
More informationuntitled
1 2 3 4 5 6 7 Point 60,000 50,000 40,000 30,000 20,000 10,000 0 29,979 41,972 31,726 45,468 35,837 37,251 24,000 20,000 16,000 12,000 8,000 4,000 0 16,795 22,071 20,378 14 13 12 11 10 0 12.19 12.43 12.40
More information-- 0 500 1000 1500 2000 2500 3000 () 0% 20% 40% 60%23 47.5% 16.0% 26.8% 27.6% 10,000 -- 350 322 300 286 250 200 150 100 50 0 20 21 22 23 24 25 26 27 28 29 -- ) 300 280 260 240 163,558 165,000 160,000
More informationサービス付き高齢者向け住宅賠償責任保険.indd
1 2 1 CASE 1 1 2 CASE 2 CASE 3 CASE 4 3 CASE 5 4 3 4 5 6 2 CASE 1 CASE 2 CASE 3 7 8 3 9 10 CASE 1 CASE 2 CASE 3 CASE 4 11 12 13 14 1 1 2 FAX:03-3375-8470 2 3 3 4 4 3 15 16 FAX:03-3375-8470 1 2 0570-022808
More information<4D F736F F D208C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
28 6 IT 26 1 326 4,499 433 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
More information★索引.indb
S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in
More informationLDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
More information<4D F736F F D2095BD90AC E93785F8C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
29 7 IT 27 339 5,199 464 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
More information『戦時経済体制の構想と展開』
1 15 15 17 29 36 45 47 48 53 53 54 58 60 70 88 95 95 98 102 107 116 v 121 121 123 124 129 132 142 160 163 163 168 174 183 193 198 205 205 208 212 218 232 237 237 240 247 251 vi 256 268 273 289 293 311
More information研究紀要 第5号
3 4 5 6 7 8 a s d f a 9 10 s d a 11 12 s d f g 13 h j a d s 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 a 35 s 36 a 37 s 38 a 39 s 40 a 41 s d 42 f 43 44 46 47 48 49 50 a s d as d 51
More information函館市_絵で見てわかる
70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183
More informationi ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
More information17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
More information(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More informationA Decade of Drastic Change 1992 2002
A Decade of Drastic Change 1992 2002 A Recording Industry Association of Japan 0 1,000 2,000 3,000 4,000 5,000 1 10 20 30 40 50 60 70 80 91 0 2,000 4,000 6,000 8,000 10,000 2001
More information001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
More information<4D F736F F D2095BD90AC E937890B68A888F4B8AB E397C394EF82CC93AE8CFC82C98AD682B782E992B28DB895AA90CD2E646F6378>
28 3 IT 1,124 1,414 9,986 1,205 247 2 6,663 6,802 3 4,155 ICD-10 p.2 26 3 4,155 1,124 10 3,628 10.62% 10 31.29%30.75%15.62% 36.31% 29.88%20.94% 928 692 412 205 6,127 4,971 3,246 2,291 1,968 1,658 35.77
More information2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
More information1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30
1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7
More informationuntitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
More informationIII
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
More informationiii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More information1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
More information1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
More information20-121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
More information入門ガイド
ii iii iv NEC Corporation 1998 v P A R 1 P A R 2 P A R 3 T T T vi P A R T 4 P A R T 5 P A R T 6 P A R T 7 vii 1P A R T 1 2 2 1 3 1 4 1 1 5 2 3 6 4 1 7 1 2 3 8 1 1 2 3 9 1 2 10 1 1 2 11 3 12 1 2 1 3 4 13
More information<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
More information2
2013 Vol.18 No.2 3 24 25 8 22 2 23 26 9 15 20 2 3 4 5 6 7 8 point1 point 2 point3 point4 10 11 point1 point 2 point 3 point 4 12 13 14 15 16 17 18 19 20 http://www.taishukan.co.jp/kateika/ 21 22 23 24
More informationSC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
More information